Holen Sie sich die Stockscreener-App
98.00
1.92%
1.85
Handel nachbörslich:
97.50
-0.50
-0.51%
Schlusskurs vom Vortag:
$96.15
Offen:
$97.47
24-Stunden-Volumen:
698.35K
Relative Volume:
1.33
Marktkapitalisierung:
$7.70B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-425.38M
KGV:
-16.75
EPS:
-5.8504
Netto-Cashflow:
$-275.21M
1W Leistung:
+0.59%
1M Leistung:
-6.25%
6M Leistung:
+26.42%
1J Leistung:
+30.70%
1-Tages-Spanne:
$97.08
$100.67
1-Wochen-Bereich:
$93.91
$100.67
52-Wochen-Spanne:
$55.53
$113.02
Nuvalent Inc Stock (NUVL) Company Profile
Firmenname
Nuvalent Inc
Sektor
Branche
Telefon
508-446-2272
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
98.00 | 7.56B | 0 | -425.38M | -275.21M | -5.8504 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-12 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-10-16 | Fortgesetzt | Stifel | Buy |
| 2025-10-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Outperform |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-03-14 | Hochstufung | UBS | Neutral → Buy |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-24 | Eingeleitet | UBS | Neutral |
| 2024-08-29 | Eingeleitet | Barclays | Overweight |
| 2024-04-17 | Eingeleitet | Jefferies | Buy |
| 2024-04-01 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-28 | Fortgesetzt | Guggenheim | Buy |
| 2024-02-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-27 | Eingeleitet | Stifel | Buy |
| 2023-08-08 | Eingeleitet | SVB Securities | Market Perform |
| 2023-07-24 | Eingeleitet | Guggenheim | Buy |
| 2023-01-18 | Eingeleitet | Wedbush | Outperform |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
Alle ansehen
Nuvalent Inc Aktie (NUVL) Neueste Nachrichten
NUVL (NASDAQ: NUVL) files Form 144 to sell Class A shares via J.P. Morgan - Stock Titan
Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc. - National Today
Hudson Bay Capital Management LP Purchases New Stake in Nuvalent, Inc. $NUVL - MarketBeat
Stop Loss: Should I set a stop loss on Nuvalent Inc2026 Volume & Capital Protection Trade Alerts - baoquankhu1.vn
Trend Report: Is Nuvalent Inc in a consolidation phase2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn
Aug Catalysts: Is Nuvalent Inc in a consolidation phase2026 Price Swings & Daily Momentum Trading Reports - baoquankhu1.vn
Nuvalent (NUVL) officer Benjamin Lane details stock, options and RSUs in Form 3 - Stock Titan
(NUVL) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL) - Yahoo Finance
Cantor Fitzgerald L. P. Makes New $1.95 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Does Nuvalent (NUVL) have the potential to rally 37.26% as Wall Street analysts expect? - MSN
Nuvalent to unveil new ROS1+ NSCLC clinical and preclinical data at AACR 2026 - Traders Union
Nuvalent to Present New Preclinical and Clinical Data for Zidesamtinib, an Investigational ROS1-Selective Inhibitor, at AACR Annual Meeting 2026 - PR Newswire
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - AOL.com
Vestal Point Sells Nuvalent Shares: Portfolio Impact and Company OutlookNews and Statistics - IndexBox
Nuvalent (NUVL) Gets a Buy from Canaccord Genuity - The Globe and Mail
Nuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally - The Motley Fool
Nuvalent's Chief Scientific Officer Sells Over 35,000 Shares - TradingView
Nuvalent (NUVL) CSO sells 35,104 shares after major option exercises - Stock Titan
Nuvalent, Inc. Holdings Raised by HighVista Strategies LLC - National Today
Nuvalent, Inc. $NUVL Holdings Raised by HighVista Strategies LLC - MarketBeat
Farallon Capital Management LLC Sells 147,000 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Braidwell LP Sells 162,894 Shares of Nuvalent, Inc. - National Today
Cantor Fitzgerald L. P. Acquires Shares of 22,500 Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent, Inc. $NUVL Position Increased by Commodore Capital LP - MarketBeat
Braidwell LP Sells 162,894 Shares of Nuvalent, Inc. $NUVL - MarketBeat
NUVL Technical Analysis & ETF Price Forecast - Intellectia AI
Inflation Data: Is Nuvalent Inc forming a bullish divergence2026 WrapUp & Real-Time Market Trend Scan - baoquankhu1.vn
Is It Time To Reassess Nuvalent (NUVL) After Recent Trial And Pipeline Updates - simplywall.st
Assessing Nuvalent (NUVL) Valuation After Widening Losses And A New US$458.4m Shelf Registration - Yahoo Finance
25,160 Shares in Nuvalent, Inc. $NUVL Acquired by Jefferies Financial Group Inc. - MarketBeat
Nuvalent (NASDAQ: NUVL) CEO sells 30K shares after option exercise - Stock Titan
Canaccord Genuity Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation - MSN
NUVL: Strong clinical data and rapid enrollment position ROS1 and ALK drugs for global launch - TradingView
(NUVL) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
American Century Companies Inc. Sells 11,767 Shares of Nuvalent, Inc. $NUVL - MarketBeat
Growth Value: Should I set a stop loss on Nuvalent IncMarket Risk Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
[144] Nuvalent, Inc. SEC Filing - Stock Titan
NUVL Earnings History & Surprises | EPS & Revenue Results | NUVALENT INC-A (NASDAQ:NUVL) - ChartMill
Citigroup Inc. Has $3.04 Million Holdings in Nuvalent, Inc. $NUVL - MarketBeat
Aug Sentiment: Will Nuvalent Inc benefit from green energy policiesWeekly Trading Summary & Daily Volume Surge Trade Alerts - baoquankhu1.vn
HC Wainwright Brokers Lift Earnings Estimates for Nuvalent - MarketBeat
NUVL: Regulatory filings and commercial launches for ALK and ROS1 NSCLC therapies are on track for 2024 - TradingView
HC Wainwright Brokers Reduce Earnings Estimates for Nuvalent - MarketBeat
NUVLForm S-8Securities to be offered to employees in employee benefit plans - mx.advfn.com
Nuvalent Outlines Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Fourth Quarter and Full Year 2025 Financial Results - mx.advfn.com
TD Asset Management Inc Increases Position in Nuvalent, Inc. $NUVL - MarketBeat
NUVL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Nuvalent Insider Sold Shares Worth $566,788, According to a Recent SEC Filing - marketscreener.com
Finanzdaten der Nuvalent Inc-Aktie (NUVL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):